BOSTON, Nov. 10, 2025 (WORLD NEWSWIRE)– Vor Biopharma Inc. (NASDAQ: VOR) (Vor Bio), a clinical-stage biotechnology business committed to changing the treatment of autoimmune illness, today revealed that it has actually begun an underwritten public offering of $100 countless shares of its typical stock. In addition, Vor Bio plans to give the underwriters a 30-day alternative to buy approximately an extra $15 countless shares of its typical stock at the general public offering rate, less underwriting discount rates and commissions. All of the shares are being provided by Vor Bio. The proposed offering undergoes market and other conditions, and there can be no guarantee regarding whether or when the offering might be finished, or regarding the real size or regards to the offering.
J.P. Morgan, Jefferies, Citigroup and TD Cowen are functioning as joint book-running supervisors for the proposed offering.
The shares of typical stock explained above are being provided by Vor Bio pursuant to a rack registration declaration submitted by Vor Bio with the Securities and Exchange Commission (SEC) that was stated reliable by the SEC on March 31, 2025. The offering might be made just by methods of a prospectus supplement and an accompanying prospectus that form a part of the registration declaration. An initial prospectus supplement and accompanying prospectus connecting to the offering will be submitted with the SEC and will be readily available on the SEC’s site situated at http://www.sec.gov. Copies of the initial prospectus supplement and the accompanying prospectus associated to this offering, when readily available, might be gotten from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717, or by e-mail at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attention: Equity Distribute Prospectus Department, 520 Madison Opportunity, New York City, NY 10022, by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717 or by means of telephone: (800) 831-9146; or TD Securities (U.S.A.) LLC, 1 Vanderbilt Opportunity, New York City, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Opportunity, Edgewood, NY 11717 or by e-mail at TDManualrequest@broadridge.com.
This news release will not make up a deal to offer or a solicitation of a deal to purchase these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such deal, solicitation or sale would be illegal previous to the registration or certification under the securities laws of any such state or other jurisdiction.
About Vor Bio
Vor Bio is a clinical-stage biotechnology business changing the treatment of autoimmune illness. The Business is concentrated on quickly advancing telitacicept, an unique dual-target combination protein, through Stage 3 medical advancement and prospective commercialization to deal with severe autoantibody-driven conditions worldwide.
Forward Looking Declarations
Particular declarations in this news release are positive declarations that include a variety of threats and unpredictabilities. These declarations might be determined by initial words such as “prepare for,” “think,” “anticipates,” “plans,” “may,” “strategy,” “should,” “based on,” “will,” “would” or words of comparable significance, or by the reality that they do not relate strictly to historic or existing realities. Such positive declarations consist of those connecting to Vor Bio’s awaited public offering, including its objective to give the underwriters a 30-day alternative to buy extra shares. For such declarations, Vor Bio declares the security of the Personal Securities Lawsuits Reform Act of 1995. Real occasions or outcomes might vary materially from Vor Bio’s expectations. Elements that might trigger real outcomes to vary materially from the positive declarations consist of, however are not restricted to, threats and unpredictabilities related to the consummation of the offering, the conclusion of the offering on the awaited terms or at all, unpredictabilities connected to market conditions, the fulfillment of traditional closing conditions connected to the offering, basic financial conditions, and those elements divulged in Vor Bio’s filings with the SEC, including its Quarterly Report on Kind 10-Q for the quarter ended June 30, 2025. These positive declarations represent Vor Bio’s judgment since the time of this release. Vor Bio disclaims any intent or commitment to upgrade these positive declarations, aside from as might be needed under relevant law.
Media & & Financier Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com